Table 2

Clinicopathological comparison of OC patients with BRCA1 wild-type and methylated promoters

Methylated (n = 12)Wild type (n = 86)P
Age57.8 ± 12.161.7 ± 12.1
Stage2.82.7
Grade3.12.8
Histology
% papillary serous50%     68%       0.21 
% Jewish 8% (1/12)35% (30/86) 0.096
% breast/ovarian cancer family syndrome0%    19.8% (17/86)0.12 
% platinum-based chemotherapy67% (8/12)68% (59/86) 0.47